HoloGraft One

HoloGRAFT ONE uses copy number variant markers, long stretches of DNA inherited in zero, one or two-copy forms. The donor-informative markers, as well as their detected amplicons, are missing in the patient. The detected amplicons are subsets of the variants, in contrast to SNP-based alternatives, where the variants are subsets of the detected amplicons. Therefore, HoloGRAFT ONE is the only dd-cfDNA monitoring method with a negative background.

Frequent dd-cfDNA monitoring in transplantation may allow early detection of allograft injury, which is expected to improve graft survival rates, and reduce the need for unnecessary invasive procedures. This unique biomarker has the promise of improving the monitoring of response to treatment or changing therapy.

• HoloGRAFT ONE eliminates the need for prior genotyping of the donor and recipient.
• Digital PCR is economical even for single-sample runs.
• HoloGRAFT ONE simultaneously measures all markers, and the test provides a comprehensive evaluation of dd-cfDNA levels.
• Direct absolute quantification of dd-cfDNA by digital PCR eliminates the need for complex library preparation, pre-amplification and expensive NGS instrumentation.

HoloGRAFT ONE measures dd-cfDNA level solely from the patient’s sample.